Business Context and Reporting Period
This Form 6-K filing by Anchiano Therapeutics Ltd. (also referenced as Chemomab Therapeutics Ltd. in metadata) covers the month of September 2019, with the report dated September 23, 2019. The Company is a foreign private issuer focused on oncology therapeutics.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or liquidity metrics for the period. The only specific financial figure disclosed relates to a new contractual obligation:
- Upfront Payment: $3 million payable to ADT Pharmaceuticals, LLC under a new Collaboration Agreement.
- Future Obligations: Additional fees upon option exercise, milestone payments, and low- to mid-single digit royalties on future product sales.
Material Changes
The primary material change reported is the execution of a Collaboration and License Agreement on September 13, 2019, between Anchiano Therapeutics, Inc. (a wholly-owned subsidiary) and ADT Pharmaceuticals, LLC. Key terms include:
- Scope: Joint research and development of novel small-molecule inhibitors targeting RAS and PDE10/β-catenin.
- Roles: Anchiano leads research, development, manufacturing, and regulatory activities; ADT assists with research in exchange for a quarterly fee.
- Option Rights: Anchiano received an exclusive option to research, develop, manufacture, and commercialize the compounds worldwide.
- Termination: Anchiano may terminate the agreement with 90 days' written notice.
Outlook, Management Commentary, and Risks
Clinical Trial Update: The Company provided an update on its pivotal Phase 2 Codex Trial. As of the filing date, 31 patients were enrolled or in active screening, with 23 patients dosed. Management estimates that data collection and the 35-patient interim analysis will be completed by the first quarter of 2020.
Risks and Contingencies: The filing notes that the summary of the Collaboration Agreement is qualified by the full text of the agreement. The Company's ability to proceed with the new compounds depends on the exercise of the option and the success of the joint development efforts.
Investor Verification Checklist
- Verify the impact of the $3 million upfront payment on the Company's current cash position and runway.
- Review the full text of the Collaboration Agreement (Exhibit 10.1) for specific milestone payment triggers and royalty calculation details.
- Monitor the timeline for the Phase 2 Codex Trial interim analysis, expected in Q1 2020.
- Confirm the Company's ability to fund the quarterly fees to ADT and future development costs.